ProSciento’s executive leadership is internationally recognized for their contributions to metabolic clinical research and development across all phases of the product development cycle.
Marcus Hompesch, M.D.
Dr. Marcus Hompesch is Chief Executive Officer and Chairman of the Board of ProSciento and has led the company since its inception in 2003. He is also editor-in-chief of the journal Endocrinology, Diabetes & Metabolism, a Wiley publication. His career and track record in metabolism-focused clinical R&D, spanning more than 25 years in academic and industry settings, includes contributions to clinical development strategies and early phase research studies for many of the diabetes and related metabolic drugs and devices on the market globally.
Brian Mooney is Chief Operating Officer at ProSciento, Inc. Mr. Mooney is a CRO executive with over 25 years of experience, much of it focused on global expansion of operations for mid to large CROs, including Chiltern, Theorem and Pharmaceutical Research Associates International (PRA). Prior to joining ProSciento, he served as Executive Vice President of Strategic Service Provision at Chiltern, a Covance company, where he oversaw the development and advancement of one of their core business segments.
Linda Morrow, M.D.
Dr. Linda Morrow is Chief Medical Officer at ProSciento, Inc. Her career in metabolism-focused clinical R&D, spanning more than 25 years, includes contributions to clinical development strategies and early phase research studies for many of the diabetes and related metabolic drugs and devices on the market globally today.
Markus Hofmann is ProSciento’s Chief Financial Officer overseeing the company’s accounting and financial operations. Mr. Hofmann has had a leadership role in ProSciento’s finance department since 2013 when he joined the company as Corporate Controller and Vice President of Financial Services.